TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study-Reference-Cited by-同舟云学术

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Published:2017-09 Issue:9 Volume:18 Page:1172-1181
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kuboki Yasutoshi,Nishina Tomohiro,Shinozaki Eiji,Yamazaki Kentaro,Shitara Kohei,Okamoto Wataru,Kajiwara Takeshi,Matsumoto Toshihiko,Tsushima Takahiro,Mochizuki Nobuo,Nomura Shogo,Doi Toshihiko,Sato Akihiro,Ohtsu Atsushi,Yoshino Takayuki

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE–3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE–3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial;Stintzing;Lancet Oncol,2016

3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

4. Repeated oral dosing of TAS–102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models;Tanaka;Oncol Rep,2014

5. The clinical pharmacology of 5-trifluoromethyl–2′-deoxyuridine;Dexter;Cancer Res,1972

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review;Frontiers in Oncology;2024-07-12

3. Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis;ecancermedicalscience;2024-07-10

4. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status;Oncotarget;2024-07-02

5. Combination of Modest Dosage of Bevacizumab with TAS-102 Provided the Comparable Efficacy in Treating Refractory Metastatic Colorectal Cancer;2024-06-20